Drug-based Therapy

OTOSTEM employs human stem cells to generate human otic cellular models to allow screening for ototoxic, otoprotective and otoregenerative compounds to develop a drug-based hearing loss treatment.

Cell-based Therapy

OTOSTEM addresses this urgent and unmet medical need for causal hearing loss therapies by focusing on human stem cell technology.

We will follow two major directions to implement a therapeutic use of human stem cell technology for hearing loss.

Human Stem Cell Technology

Stacks Image 808
We will follow two major directions to implement a therapeutic use of human stem cell technology for hearing loss.

Welcome to the OTOSTEM Website

The lack of human otic cell models represents a significant roadblock hampering the development of drug-based or cell-based therapies. Hearing impairment is the most frequent
human sensory deficit and is mainly caused by the irreversible loss of neurosensory cells in the cochlea.

OTOSTEM addresses this urgent and unmet medical need for causal hearing loss therapies by focusing on human stem cell technology.
Innovative Medicines Initiative (IMI) 2 Call 13: Indicative Topics Published
IMI 2 has just published a list of indicative topics for the call 13 which is foreseen to be launched before the end of the year.The followi...
OTOSTEM releases its second publishable summary
The second publishable summary of OTOSTEM is now available online.This document summarises the progress in the second 18 months of the project.
New publications by OTOSTEM
Three new research articles by OTOSTEM partners from Uppsala University, Massachusetts Eye and Ear Infirmary( MEEI) and Stanford University have been...

The OTOSTEM project has received funding from the European Community's Seventh Framework Programme under grant agreement No. 603029.